VEGF inhibitor high-dose formulation sustains disease control, extends treatment interval in nAMD
21 Mar 2025
byProf. Marion Munk, Specialist in Ophthalmology Chief Scientific Officer, Gutblick Ophthalmology Centre, Bern, Switzerland
An 89-year-old male with bilateral (OU) pseudophakia and primary open-angle glaucoma (POAG) was being monitored for neovascular age-related macular degeneration (nAMD) in the left eye (OS). He used an Amsler grid to monitor his visual function.
VEGF inhibitor high-dose formulation sustains disease control, extends treatment interval in nAMD
21 Mar 2025
